Brazilian Breast Cancer Study Group (GBECAM) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04540692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Brazilian Breast Cancer Study Group (GBECAM)